Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISTACAT
ISRCTN23804370Phase 2Completed
- Sponsor
- NHS National Services Scotland
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of saracatinib, anastrozole and exemestane in breast cancer (2 arms), sponsored by NHS National Services Scotland. Primary endpoints: Progression-free survival and Time to progression. Started Mar 2012; status: completed.
02
Drugs
saracatinibanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN23804370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23804370.